APIMEDS PHARMACEUTICALS US, INC. Shareholders' Equity
APIMEDS PHARMACEUTICALS US, INC. (APUS) had Shareholders' Equity of $106.45 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-14
- 2026-06-30: Stockholders' Equity Attributable to Parent $106.45M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $126.52M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $153.35M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $8.16M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $106.45M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $126.52M 10-Q · filed 2026-08-14 |
| 2025-12-31 | $153.35M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $8.16M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $9.74M 10-Q · filed 2026-08-14 |
| 2025-03-31 | -$1.76M 10-Q · filed 2026-08-14 |
| 2024-12-31 | -$1.36M 10-Q · filed 2026-08-14 |
| 2024-09-30 | -$1.05M 10-Q · filed 2025-11-12 |
| 2024-06-30 | -$713.97K 10-Q · filed 2025-11-12 |
| 2024-03-31 | -$264.60K 10-Q · filed 2025-11-12 |
| 2023-12-31 | $31.87K 10-K · filed 2026-05-04 |
| 2022-12-31 | -$713.61K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |